Literature DB >> 11781259

P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia.

Elena Adinolfi1, Loredana Melchiorri, Simonetta Falzoni, Paola Chiozzi, Anna Morelli, Alessia Tieghi, Antonio Cuneo, Gianluigi Castoldi, Francesco Di Virgilio, Olavio R Baricordi.   

Abstract

Human leukocytes express a receptor for extracellular nucleotides, named P2X7R, that in lymphocytes can either mediate cell death or proliferation, depending on the level of activation. The authors have investigated P2X7R expression and function in 21 patients affected by B-cell chronic lymphocytic leukemia, 13 with an evolutive and 8 with an indolent variant of the disease. Resting cytoplasmic Ca++ concentration was significantly higher in lymphocytes from patients with the evolutive compared with indolent variant. Furthermore, in the former, P2X7R stimulation triggered a Ca++ influx significantly larger. Higher Ca++ influx correlated with an increased P2X7R expression in the lymphocytes from patients with the evolutive form. Finally, incubation in the presence of extracellular adenosine triphosphate decreased spontaneous proliferation of lymphocytes from patients affected with the evolutive variant but had no effects on lymphocytes from patients with the indolent form. These results suggest that expression and function of P2X7R may correlate with the severity of B-cell chronic lymphocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781259     DOI: 10.1182/blood.v99.2.706

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  79 in total

1.  P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cells.

Authors:  Safina Gadeock; Aleta Pupovac; Vanessa Sluyter; Mari Spildrejorde; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2012-06-05       Impact factor: 3.765

Review 2.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

Review 3.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

Review 4.  Purinergic trophic signalling in glial cells: functional effects and modulation of cell proliferation, differentiation, and death.

Authors:  Davide Lecca; Stefania Ceruti; Marta Fumagalli; Maria P Abbracchio
Journal:  Purinergic Signal       Date:  2012-04-12       Impact factor: 3.765

Review 5.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

6.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 7.  Expression and function of P2 receptors in hematopoietic stem and progenitor cells.

Authors:  Wenli Feng; Lina Wang; Guoguang Zheng
Journal:  Stem Cell Investig       Date:  2015-07-30

Review 8.  Inhibition of P2X(7) receptors by divalent cations: old action and new insight.

Authors:  Lin-Hua Jiang
Journal:  Eur Biophys J       Date:  2008-04-15       Impact factor: 1.733

9.  Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function.

Authors:  Chengqun Sun; Jessica Chu; Sarita Singh; Russell D Salter
Journal:  Purinergic Signal       Date:  2009-10-17       Impact factor: 3.765

10.  P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways.

Authors:  Yan Qu; George R Dubyak
Journal:  Purinergic Signal       Date:  2009-02-03       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.